# The Study Will Evaluate Average 24-hr Sodium Excretion During Dapagliflozin Treatment in Patients With Type 2 Diabetes Mellitus With Preserved or Impaired Renal Function or Non-diabetics With Impaired Renal Function.

> **NCT03152084** · PHASE4 · TERMINATED · sponsor: **AstraZeneca** · enrollment: 24 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2
- Kidney Function Tests

## Interventions

- **DRUG:** Dapagliflozin

## Key facts

- **NCT ID:** NCT03152084
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-07-12
- **Primary completion:** 2020-03-20
- **Final completion:** 2020-03-20
- **Target enrollment:** 24 (ACTUAL)
- **Why stopped:** Poor recruitment.
- **Last updated:** 2021-05-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03152084

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03152084, "The Study Will Evaluate Average 24-hr Sodium Excretion During Dapagliflozin Treatment in Patients With Type 2 Diabetes Mellitus With Preserved or Impaired Renal Function or Non-diabetics With Impaired Renal Function.". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03152084. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*